GEN-MKT-18-7897-A
Oct 11, 2017 | Blogs, Technology | 0 comments
If you are working with complex assays that demand exceptionally selective quantitative and qualitative performance, sometimes even the most powerful LC-MS/MS technology can’t always cut it alone.
Perhaps you are struggling to separate isobaric species, isolate challenging co-eluting analytes or reduce high background noise? Regardless of your challenge, the outcome is the same. You probably aren’t getting the levels of quantitation or characterization you need, so method development has become cumbersome, and workflow performance is suffering.
Now you can bring a new dimension of selectivity to your LC-MS/MS analysis on select SCIEX Triple Quad™, QTRAP® and TripleTOF® Systems with SelexION® Differential Mobility Separation (DMS) Technology. The SelexION DMS cell:
Harness the power of differential mobility separations to simplify your sample preparations, while achieving unprecedented levels of selectivity. Find out more by downloading the SelexION brochure.
How does it work?Gas phase differential mobility separation within the SelexION device planar mobility cell is based on the ion’s size and shape, and the difference between their unique differential mobilities across high and low energy fields. Gas phase separation occurs prior to entering the mass analyzer where the compounds are then further separated by m/z ratios.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network